MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202411004994 A) filed by Indian Council Of Medical Research; and Manipal College Of Pharmaceutical Sciences, New Delhi, on Jan. 24, 2024, for 'formulation development of solid self-emulsifying drug delivery system (solid sedds) of luliconazole using hot melt extrusion technology.'
Inventor(s) include Dr. Vamshi Krishna Tippavajhala; Ashay Manisha Shailendrakumar; and Dr. Srinivas Mutalik.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "Formulation development of solid self-emulsifying drug delivery system (Solid SEDDS) of Luliconazole using hot melt extrusion technology The present invention is directed to solid self-emulsifying drug delivery system (Solid SEDDS) to enhance the solubility of Luliconazole by entrapping the liquid-emulsion inside the solid matrix using hot melt extrusion technology. The solidification process by hot melt extrusion that operates in a temperature range of 50 C to 120 C. This is a twin-screw process where screws co-rotate at 250 rpm, generating the solid product as granules. These granules could be directly compressed as tablets, filled in capsules, or used as granules for reconstitution (GFR). It is an immediate release product showing better solubility and bioavailability compared to plain drug. The optimized formula of Solid SEDDS includes a solid base composed of a HPMC E5 LV, Prosolveasytab, and PEG 4000 (Total 225mg), into which 125 microliters of Liquid SEDDS containing 10 mg of Luliconazole is entrapped. The optimized Liquid SEDDS is composed of Capryol 90(Oil), Tween 20(Surfactant) and PEG 200 (Co-surfactant)."
Disclaimer: Curated by HT Syndication.
